Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
申请人:Glaxosmithkline LLC
公开号:EP2404603A1
公开(公告)日:2012-01-11
Novel substituted 2,4,8-trisubstituted -8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
新型取代的 2,4,8-三取代-8H-吡啶并[2,3-d]嘧啶-7-酮化合物及组合物,作为 CSBP/p38 激酶抑制剂用于治疗。